June 18, 2018
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

An Important Word from Quality Assurance About Protocol Amendments Read more

Hurry - Only 4 more days to Pre-Register for the NRG Oncology Semiannual Meeting!
The pre-registration deadline is June 22nd. Read more.

 

NRG Oncology Semiannual Meeting

Hurry – Only 4 more days to Pre-Register!
We hope you can join us for the NRG Oncology Semiannual Meeting, July 12-14, 2018, at the Philadelphia Marriott Downtown in Philadelphia, PA. The Pre-Registration deadline is June 22, 2018. The hotel registration deadline is June 20, 2018. We kindly ask that everyone please pre-register online for this meeting before the deadline! Registering onsite at the meeting will incur an additional $50 fee. Registration and meeting information is available on the NRG Oncology website.


Meeting Highlights

  • Summer Symposium: Thursday, July 12 – 8am-3pm Read more
  • Digital Health and Personal Connected Health MinisymposiumThursday, July 12 – 1-3pm Read more
  • Health Disparities Workshop Special Session: Intervening on the Financial Toxicity of Cancer Care - Friday, July 13 – 7-9am Read more
  • Scientific Session: Friday, July 13 – 8-10am Read more
  • Social Media Workshop: Friday, July 13 – 10-11:30am *New Session! Read more
  • Workshops! Plan to Attend! NRG-BR005 and NRG-BR003/NSABP B-55/NRG-BR004 (details posted to the NRG Oncology  meeting page)

ACTIVATIONS
GYNECOLOGIC
NRG-GY007: Reactivation - June 18, 2018; Version date: April 6, 2018 (posted on NRG Oncology).

NRG-GY009: Reactivation June 18, 2018; Version date: March 19, 2018 (posted on CTSU).

CLOSURES AND SUSPENSIONS
HEAD & NECK
NRG HN004: “Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin,” temporarily closed to accrual on June 13, 2018, because the first dose level of the lead-in cohort has enrolled 10 patients. NRG-HN004 will remain closed for approximately 3 months for toxicity assessment.

AMENDMENTS
GYNECOLOGIC
GOG-0225: Amendment 8; Version date: June 8, 2018 (posted on NRG Oncology).

OTHER PROTOCOL NOTICES
1. An Important Word from Quality Assurance About Protocol Amendments
In order to avoid problems at audit and at the time of patient enrollments, site staff must more closely monitor the NRG Oncology Weekly Broadcast for protocol amendments.  Amendments are announced in the weekly (typically Monday) broadcast under the heading, Protocol Activity, or sometimes, they are announced during the week in a separate broadcast.  Regardless, the location/website where the amendment is posted is included in the announcement. We understand some staff have problems receiving the e-mail broadcasts; so please spread the word that broadcasts are posted to the NRG Oncology website under the News tab and can be monitored from there.

2. SWOG Protocol S1613: "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification" is open to patient enrollment. It is available on the CTSU menu with Dr. Marwan Fakih, a member of the NRG Oncology Colorectal Committee, as the NRG Oncology Champion. Dr. Fakih was actively involved in the development and refinement of this study and it cannot be accomplished without the NCTN given the infrequency of this patient population. We encourage our members to enroll eligible patients to this important trial. Although NRG Oncology is not the lead group on this trial, your institution can select NRG Oncology as the group credited with accrual at the time of enrollment. If NRG Oncology is selected, the enrollment will count towards membership requirements.

3. NRG-HN004: Lead-In Weekly Accrual Summary is available under the Patient Enrollment tab of the CTSU website.

4. VTOC Training
The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for August 15, 2018.


DRUG SAFETY UPDATES
Safety updates have been issued for the following studies:

DRUG NAME

PROTOCOL

WEBSITE FOR
SAFETY REPORTS

Veliparib

NRG-GI002

CTSU

NCI Social Media Workshop Videocast now available for viewing
The National Cancer Institute sponsored “At the Crossroads of Social Media and Clinical Trials: A Workshop on the Future of Clinician, Patient and Community Engagement” on June 7-8, 2018. This highly interactive, two-day workshop included clinical trial experts, community oncologists, cancer advocates, patients, and social media and communications experts.  Participants explored innovative ways to connect with their communities to enhance awareness and understanding of clinical trials through social media.  A member from every National Clinical Trials Network (NCTN) presented their group’s social media efforts and focus. The agenda can be viewed here. To view a videocast of the workshop, use these links: Day 1, Day 2.
NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES
Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, Choy H. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol. 2018 May 31. doi: 10.1001/jamaoncol.2018.1258. [Epub ahead of print] PubMed PMID: 29852036. Read more

Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018 May 31. doi: 10.1001/jamaoncol.2018.1251. [Epub ahead of print] PubMed PMID: 29852037. Read more

Regine WF, Winter KA, Abrams RA, Safran H, Kessel IL, Chen Y, Fugazzi JA, Donnelly ED, DiPetrillo TA, Narayan S, Plastaras JP, Gaur R, Delouya G, Suh JH, Meyer JE, Haddock MG, Didolkar MS, Padula GD, Johnson D, Hoffman JP, Crane CH. Post-resection CA19-9 and Margin Status as Predictors of Recurrence after Adjuvant Treatment for Pancreatic Carcinoma: Analysis of NRG Oncology RTOG Trial 9704. Advances in Radiation Oncology, 3(2):154-162. DOI: 10.1016/j.adro.2018.01.003. Read more

PUBLICATIONS REMINDERS
Please note the following upcoming meeting and abstract submission deadline dates
Upcoming Meetings
Multinational Association of Supportive Care in Cancer (MASCC); Jun 28-30, 2018; Vienna, Austria

Society for Neuro-Oncology (SNO); Nov 15-18, 2018; New Orleans, LA

Upcoming Abstract Submission Deadlines
American Society for Radiation Oncology (ASTRO); Oct 21-24, 2018; San Antonio, TX; Late-breaking Aug 1, 2018

European Society for Medical Oncology (ESMO); Oct 19-23, 2018;Munich, Germany; Late-breaking Sep 17, 2018

San Antonio Breast Cancer Symposium (SABCS); Dec 4-8, 2018; San Antonio, TX; due to publications committee Jun 19, 2018; meeting abstracts submission deadline June 29, 2018 [Dropdead Deadline July 3, 2018 (10 am CDT)]

Society of Clinical Research (SOCRA); Sep 28-30, 2018; New Orleans, LA; due to publications committee July 6, 2018; meeting abstracts submission deadline July 20, 2018

NRG Oncology is proud to be an active participant of #CancerMoonShot.
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address